このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Sacral Erector Spinae Plane Block for Catheter-Related Bladder Discomfort After HoLEP

2026年11月12日 更新者:Kadriye Dıvrak、Ankara Etlik City Hospital

Evaluation of the Effect of Bilateral Sacral Erector Spinae Plane Block on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Holmium Laser Enucleation of the Prostate

Catheter-related bladder discomfort (CRBD) is common after holmium laser enucleation of the prostate (HoLEP). This single-center, randomized, controlled, assessor-blinded trial evaluates whether an ultrasound-guided bilateral sacral erector spinae plane (S-ESP) block performed before general anesthesia reduces the incidence of CRBD compared with general anesthesia alone in men aged 50 to 80 years undergoing elective HoLEP. The primary outcome is the incidence of CRBD at 1 hour after surgery.

調査の概要

詳細な説明

Catheter-related bladder discomfort (CRBD) is a common and distressing postoperative symptom complex in male patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP), characterized by a suprapubic burning sensation, an urge to void, and involuntary bladder spasms due to three-way urinary catheterization and continuous bladder irrigation. The sacral erector spinae plane (S-ESP) block is an ultrasound-guided interfascial plane block that targets the S2-S4 sacral nerve roots, which provide both somatic (via the pudendal nerve) and visceral parasympathetic (via pelvic splanchnic nerves) innervation to the lower urinary tract. While current evidence regarding the efficacy of the S-ESP block against a no-block control group in HoLEP surgery is limited, blocking these sacral pathways may effectively modulate afferent bladder stimuli.

A total of 100 male patients aged 50 to 80 years with ASA physical status I-III scheduled for elective HoLEP surgery under general anesthesia will be randomly assigned in a 1:1 ratio to either the S-ESP block group (Group S, n=50) or the standard care control group (Group G, n=50) using computer-generated randomization and sealed opaque envelopes.

Patients in Group S will be placed in the prone position approximately 30 minutes before surgery under standard monitoring. Using a convex ultrasound transducer (GE HealthCare C1-5 probe) in a longitudinal paramedian orientation at the S2 intermediate sacral crest level, a 22G 80-100 mm echogenic block needle will be advanced in-plane in a craniocaudal direction into the fascial plane between the erector spinae aponeurosis and the sacral crest. Following hydrodissection with 1-2 mL normal saline and negative aspiration, 20 mL of 0.25% bupivacaine will be injected on each side (total 40 mL, 100 mg; not exceeding the maximum safe dose of 2 mg/kg). Sensory blockade will be assessed 30 minutes after block completion via pinprick testing over the bilateral S2-S4 dermatomes.

Both groups will receive a standardized general anesthesia protocol: induction with IV fentanyl (1 mcg/kg), propofol (2-2.5 mg/kg), and rocuronium (0.3 mg/kg) to facilitate laryngeal mask airway (LMA) insertion, followed by maintenance with 1 MAC sevoflurane and titrated remifentanil infusion (0.05-0.2 mcg/kg/min). Approximately 30 minutes before the end of surgery, all patients will receive IV paracetamol (1 g) and IV tramadol (100 mg) for multimodal analgesia, followed by routine postoperative IV paracetamol (1 g twice daily).

An independent anesthesiologist blinded to group allocation will assess postoperative outcomes at 30 minutes and at 1, 2, 4, 6, 12, and 24 hours. If the Visual Analog Scale (VAS) pain score is ≥4, IV tramadol (1 mg/kg, up to 400 mg/day) will be administered as rescue analgesia. If the CRBD score is ≥2 after excluding mechanical catheter obstruction, rescue antispasmodic or antimuscarinic medication will be administered. Quality of recovery will be evaluated at 24 hours using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T).

研究の種類

介入

入学 (推定)

100

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Derya Ozkan, Prof., MD
  • 電話番号:00905425843638
  • メール:derya_z@yahoo.com

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

Inclusion Criteria:

  • Male patients aged between 50 and 80 years
  • American Society of Anesthesiologists (ASA) physical status class I to III
  • Scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP) surgery under general anesthesia
  • Patients who agree to participate in the study and sign the written informed consent form

Exclusion Criteria:

  • Age under 50 years or over 80 years
  • ASA physical status class IV or higher
  • Known hypersensitivity or allergy to local anesthetics
  • History of chronic opioid use
  • Chronic pain syndrome
  • History of peripheral neuropathy, sacral neurological disease, or neurogenic bladder
  • Overactive bladder or prominent preoperative bladder irritation symptoms
  • History of previous prostate, bladder neck, or lower urinary tract surgery
  • Active urinary tract infection
  • Anticoagulant/antiplatelet use that contraindicates block administration according to current regional anesthesia guidelines, or clinically significant coagulopathy
  • Infection or severe dermatological lesion at the block application site
  • Severe renal failure (eGFR < 30 mL/min/1.73m2) or clinically significant hepatic failure
  • Cognitive impairment, communication difficulty, or psychiatric/neurological condition preventing postoperative assessments
  • Anticipated need for postoperative intensive care unit admission
  • Presence of a preoperative indwelling urinary catheter
  • Emergency surgery
  • Patient refusal or withdrawal of consent

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:S-ESPB Group

Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia.

Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia

アクティブコンパレータ:Standard Care Group

Standardized general anesthesia without any block or sham injection.

Standardized general anesthesia without any block.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Catheter-Related Bladder Discomfort (CRBD) at Postoperative 1 Hour
時間枠:1 hour after surgery

CRBD is graded on a 4-point scale: 0 = none; 1 = mild (reported only on questioning); 2 = moderate (reported spontaneously, without behavioral responses); 3 = severe (reported spontaneously with behavioral responses such as strong verbal response, flailing limbs or attempts to remove the catheter). Incidence is the proportion of patients with a score of 1 or higher.

1 hour after surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of CRBD at other time points
時間枠:30 minutes and 2, 4, 6, 12 and 24 hours after surgery

Proportion of patients with CRBD score of 1 or higher

30 minutes and 2, 4, 6, 12 and 24 hours after surgery
Severity of CRBD
時間枠:30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

CRBD severity will be graded on a 4-point ordinal scale from 0 (none) to 3 (severe). Moderate-to-severe CRBD is defined as a score ≥2.

30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
Postoperative pain score
時間枠:30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

Postoperative pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain).

30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
Intraoperative remifentanil consumption
時間枠:Intraoperative period

Total amount of intraoperative remifentanil consumed, recorded in micrograms (mcg) and normalized to body weight and duration (mcg/kg/hour).

Intraoperative period
Total Postoperative Rescue Analgesic Consumption
時間枠:First 24 hours after surgery

Total intravenous tramadol dose in milligrams

First 24 hours after surgery
Time to First Rescue Analgesic Request
時間枠:First 24 hours after surgery

Minutes from end of surgery to first rescue tramadol dose

First 24 hours after surgery
Antispasmodic or antimuscarinic requirement
時間枠:First 24 hours after surgery

Proportion of patients requiring additional antispasmodic or antimuscarinic medication for persistent moderate-to-severe CRBD (score ≥2)

First 24 hours after surgery
Incidence of Postoperative Nausea and Vomiting (PONV) and Other Adverse Events
時間枠:First 24 hours after surgery

Number and percentage of participants experiencing postoperative nausea and vomiting (PONV) or any block- or anesthesia-related adverse events.

First 24 hours after surgery
Postoperative Quality of Recovery Score (QoR-15T)
時間枠:At 24 hours after surgery

Quality of recovery will be evaluated using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T). Total scores range from 0 to 150, with higher scores indicating better postoperative recovery quality.

At 24 hours after surgery

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Derya Ozkan, Prof., MD、Ankara Etlik City Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月19日

一次修了 (推定)

2027年3月16日

研究の完了 (推定)

2027年3月31日

試験登録日

最初に提出

2026年11月12日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

All personal data will be anonymized and individual participant data will not be made publicly available in accordance with institutional ethics committee approval.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する